BetterLife Pharma Inc. announced that a joint application to the Mitacs Accelerate program, in collaboration with Dr. Argel Aguilar-Valles at Carleton University (Carleton) Department of Neuroscience, was successfully funded for research into the anti-depressant effects and mechanism of action ("MOA") of BETR-001 in preclinical models of depression. BETR-001 is a second-generation Lysergic Acid Diethylamide ("LSD") derivative molecule that BetterLife believes will mimic the therapeutic potential of LSD without causing psychedelic effects, such as hallucinations.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0765 USD | +6.45% | +2.68% | +59.38% |
Apr. 03 | BetterLife Pharma Inc. announced that it has received CAD 1.168 million in funding | CI |
Mar. 04 | BetterLife Pharma Inc. announced that it expects to receive CAD 0.1 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
+59.38% | 8.34M | |
-2.15% | 103B | |
+0.77% | 95.71B | |
+1.69% | 22.02B | |
-17.09% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.93% | 15.52B | |
+3.54% | 13.86B | |
+34.39% | 12.04B |
- Stock Market
- Equities
- BETRF Stock
- News BetterLife Pharma Inc.
- BetterLife Pharma Inc. Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies